There is increasing evidence that endothelial dysfunction is involved in refractoriness of acute GvHD (aGvHD). Here we investigated the hypothesis that another endothelial complication, transplant-associated thrombotic microangiopathy (TMA), contributes to the pathogenesis of aGvHD refractoriness. TMA was retrospectively assessed in 771 patients after allogeneic stem cell transplantation (alloSCT). Incidences of TMA and refractory aGvHD were correlated with biomarkers of endothelial damage obtained before alloSCT for patients receiving or not receiving statin-based endothelial prophylaxis (SEP). Diagnostic criteria for TMA and refractory aGvHD were met by 41 (5.3%) and 76 (10%) patients, respectively. TMA was overrepresented in patients with refractory aGvHD (45.0 vs 2.3% in all other patients, P o0.001). TMA independently increased mortality. Elevated pretransplant suppressor of tumorigenicity-2 and nitrates along with high-risk variants of the thrombomodulin gene were associated with increased risk of TMA. In contrast, SEP abolished the unfavorable outcome predicted by pretransplant biomarkers on TMA risk. Patients on SEP had a significantly lower risk of TMA (P = 0.001) and refractory aGvHD (P = 0.055) in a multivariate multistate model. Our data provide evidence that TMA contributes to the pathogenesis of aGvHD refractoriness. Patients with an increased TMA risk can be identified pretransplant and may benefit from pharmacological endothelium protection.
INTRODUCTION
Acute GvHD (aGvHD) is a life-threatening complication after allogeneic stem cell transplantation (alloSCT). In particular, patients with refractory GvHD that does not respond to highdose steroid therapy often have a fatal prognosis.
1,2 A growing body of evidence suggests that endothelial damage contributes to refractoriness of GvHD. 3 Our group has previously reported that steroid refractoriness correlates with markers of endothelial vulnerability, such as angiopoietin-2 (ANG2) and serum nitrates. 4, 5 Moreover, genetic variants within the recipient's thrombomodulin gene (THBD) associate with mortality of aGvHD. 6 However, the cause of the endothelial damage associated with mortality after aGvHD is currently unknown.
Similar to GvHD, transplant-associated thrombotic microangiopathy (TMA) is another serious complication after alloSCT linked to high mortality rates. 7 TMA is a microvascular disorder characterized by renal injury in combination with hemolytic anemia and microthrombosis with platelet consumption. Notably, TMA also associated with episodes of aGvHD 8 and is thought to be a clinical manifestation of endothelial cell injury in multiple target organs. 9, 10 Therefore, TMA may be a possible link between endothelial damage and GvHD refractoriness.
Protein suppressor of tumorigenicity-2 (ST2) was recently identified as the most robust plasma biomarker predicting resistance to GvHD therapy. 11 Soluble ST2 is a member of the interleukin-1 receptor family with interleukin-33 as its ligand and is produced by endothelial cells. 12, 13 In a long-term follow-up of stable ischemic heart disease, ST2 was predictive of all-cause and cardiovascular mortality independent of accepted clinical indicators and other biomarkers. 14 In addition, the membrane-bound ST2 receptor (interleukin-33/ST2 axis) was reported to exert specific immunological effects including augmentation of effector T-cell responses during aGvHD in murine models. 15 In the present study, we tested whether the presence of TMA associated with GvHD refractoriness and biomarkers of endothelial damage. We show that TMA is strongly over-represented in patients with refractory GvHD and is characterized by endothelial markers ST2 and soluble thrombomodulin (sCD141). Moreover, already high pretransplant serum levels of ST2 associate with risk of TMA. A statin-based endothelium protection (SEP) associated with reduced TMA incidence in multivariable Cox regression.
PATIENTS AND METHODS

Patient eligibility
Patients were eligible for this study if they had undergone alloSCT between September 2001 and June 2014 at the University of Heidelberg. Written informed consent to prospective blood sample and retrospective data collection was obtained for all eligible patients and was approved by the Institutional Review Board according to the Declaration of Helsinki.
GvHD prophylaxis, treatment and supportive care aGvHD was clinically and histologically diagnosed and graded using standard clinical criteria. 16 Steroid-refractory GvHD was defined as histologically confirmed disease that did not respond to standard prednisone therapy (2 mg/kg body weight, for intestinal GvHD combined with mycofenolate mofetil (MMF) 2 g/day) and required second-line salvage immunosuppressive therapy, which was generally pentostatin. 4 Our clinical definition also included GvHD patients who progressed at time points later than 3-7 days after initiating steroid therapy. As per in-house policy, all patients transplanted after January 2010 routinely received pravastatin (20 mg/day) starting at day 1 before alloSCT, in order to reduce calcineurin inhibitor-associated cardiovascular morbidity. 17 In addition, ursodeoxycholic acid (UDCA) was routinely added after June 2010 to protect patients from veno-occlusive disease. 18 GvHD prophylaxis of patients with and without statin-based endothelial protection is shown in Supplementary Table 1. Diagnosis of TMA and CKD The diagnoses of TMA and chronic kidney disease (CKD) were retrospectively assigned by an expert nephrologist (MZ) blinded to the patients GvHD status. TMA was diagnosed on the basis of international consensus criteria, 19, 20 if all of the following parameters were present; an otherwise unexplained ⩾ 50% rise in creatinine along with a ⩾ 50% increase in serum lactate dehydrogenase levels (or a pre-existing lactate dehydrogenase above 400 U/L), a drop of ⩾ 50% in platelet counts (or a pre-existing platelet count below 50/nL) and at least 4‰ schistocytes. Within this retrospective cohort, calcineurin inhibitors were exchanged (cyclosporin to low-dose tacrolimus or sirolimus), but not withdrawn when TMA developed. CKD was diagnosed according to the international guidelines for nephrology (Kidney Disease: Improving Global Outcomes (KDIGO)) 21 as impairment of renal function over a period of time of at least 3 months with a glomerular filtration rate under 60 mL/min in the absence of TMA.
ELISA and multiplex analyses
Serum levels of the following endothelial markers were measured by ELISA: sCD141 (soluble thrombomodulin, Diaclone, Besançone, France), suppressor of tumorigenicity-2 (ST2), interleukin-33 (R&D Systems Europe Ltd, Abingdon, UK) and vascular endothelial growth factor (R&D Systems). Vascular endothelial growth factor levels were normalized to thrombocyte counts, as vascular endothelial growth factor is primarily stored within thrombocytes and released during serum production. Complement C3 and C4 serum levels were measured by turbidimetry (Siemens Healthcare Diagnostics, Eschborn, Germany).
Genetically high-risk patients were identified recently. 6 Recipient's gene variants of the thrombomodulin gene THBD (single-nucleotide polymorphisms (SNPs) rs1962, rs1042579 and rs1042580) were shown to associate with higher risk of non-relapse mortality (NRM) after aGvHD. 6 These data are here reanalyzed with the endpoint TMA.
Statistical analysis
Patient and treatment characteristics were compared for categorical and non-categorical data using Fisher's and Kruskall-Wallis test, respectively. To compare serum markers measurements between different groups (for example, with or without statin), the Kruskal-Wallis test was used. Wilcoxon signed-rank test was applied for all paired measurements.
Cox regression analysis was applied for overall survival (OS). Cause-specific Cox regression analysis was applied for time to relapse, NRM and time to TMA. Relapse and NRM were considered as competing risk events. Relapse without TMA and death in remission without TMA were competing events for TMA. In these models, TMA, CKD and refractory aGvHD that occurred after alloSCT were used as time-dependent variables. Univariable associations between occurrence of TMA, CKD and OS were represented by Simon-Makuch plots. 22 Prognostic impact of time-dependent TMA or CKD on OS, relapse incidence and NRM was evaluated on the basis of hazard ratios (HRs) with 95% confidence interval (CI) from Cox's proportional hazards regression. The proportional hazards assumption was tested. 23 In competing events situations, cumulative incidences of relapse and NRM were estimated using the Aalen-Johansen estimator.
Correlation analysis of time to event variables TMA and aGvHD is not feasible with the competing event 'death without previous TMA or GvHD ' . In an alternative approach, we defined a fixed time interval of 1 year since transplantation, counted occurrence of TMA and aGvHD in this time period and omitted patients who died without having TMA and aGvHD within this period. This resulted in a 3 × 2 table: TMA within the first year (no TMA/TMA) vs aGvHD within the first year ('none', 'sensitive 1-4' and 'refractory'). The co-incidence was then tested using the Fisher's exact test. This approach is used as an approximation for the correlation analysis of the two time-to-event variables within a competing risks situation.
Multistate models were used to model the prognostic impact of statin treatment and other covariables on TMA occurrence and on acute refractory GvHD occurrence with alloSCT as the initial state and relapse/ death as an absorbing state. 24 Age, disease stage by European Blood and Marrow Transplantation (EBMT) score criteria, donor type, donor sex, strength of conditioning therapy and MMF as GvHD prophylaxis were included as baseline covariables.
For dichotomization of pretransplant serum markers, published thresholds of 1000 pg/mL for ANG2 and 26.5 μM for nitrates were used. 3, 5 As no published threshold was available for ST2, the optimal threshold (1180 pg/mL) was found using maximally selected logrank statistics according to time-to-TMA as an endpoint. To avoid the overestimation of effects, bias correction together with bootstrap resampling for estimation of the variance were applied. 25 Univariate cause-specific Cox proportional hazards regression was used to investigate the association of ST2, ADMA, ANG2 and THBD SNPs with time to TMA.
Calculations were done using the following statistical software: 'environment R', version 3.1.2, together with the R packages 'etm', version 0.6-2; 'rms', version 4.3-0; cmprsk, version 2.2-7; survival, version2.38-3; maxstat, version 0.7-22; mstate version 0.2.7; coin version 1.0-24; and prodlim version 1.5.1. All statistical tests were two-sided. Values of P o0.05 were considered statistically significant.
RESULTS
Patient characteristics
Overall, 771 patients were eligible for this study, with a median patient follow-up of 49.2 months (95% CI 44.6-54.7). Of these, 415 patients received pravastatin prophylaxis and 350 received concomitant UDCA prophylaxis. Before January 2010, 27 patients received statin prophylaxis due to pre-existing cardiac disorders. Although UDCA did not appear to contribute to the effects on NRM and TMA observed with statins ( Supplementary Figure 1) , this study cannot conclusively distinguish the specific contribution of the two candidates and therefore combines both prophylactic drugs into the term 'statin-based endothelium protection (SEP)'.
This SEP cohort was significantly older in age, had lower proportions of related donors for transplantation and a lower proportion of high-risk disease as compared with intermediate stages. The shift from high-risk to intermediate-risk disease scores did not relate to AML (P = 0.309), ALL (P = 0.675) or myeloproliferative neoplasms (P = 0.317), but only to lymphoma (P o 0.001) and multiple myeloma (P o0.001) patients. This may be related to better tools for achieving intermediate stage remissions in lymphatic diseases (defined as second complete remission or partial remission, or stable disease), so that transplantations in progressive disease have become less common over the last years for these entities. Patient baseline characteristics are summarized in Table 1 . At least one episode of aGvHD grade I-IV occurred in 313 patients (41%) and became refractory in 76 patients (10%). The median time interval from alloSCT to diagnosis of aGvHD was 1.3 months (range, 0.05-36.1 months). Refractory aGvHD was diagnosed 1.2 months (range, 0.16-12.4 months) after transplantation. GvHD prophylaxis differed between patients with and without SEP: a higher proportion of SEP patients had MMF and a lower proportion received methotrexate as GvHD prophylaxis (Supplementary Table 1 ).
TMA and CKD incidence, and impact on survival Of 771 eligible patients, 41 (5.3%) met the diagnostic criteria for TMA and 76 (9.9%) for CKD. The median time from alloSCT to diagnosis of TMA was 1.8 months (range, 0.05-36.0 months). CKD was diagnosed 1.8 months (range, 0.0-72.0 months) after transplantation. Occurrence of TMA was associated with reduced OS (HR 4.72, 95% CI 3.42-6,50, Po 0.001; time-dependent Cox regression) and increased NRM (cause-specific HR 4.19, 95% CI 2.79-6.30, P o 0.001), whereas occurrence of CKD had no Transplant-associated thrombotic microangiopathy and acute GVHD M Zeisbrich et al significant impact on outcome (OS, HR 0.94, 95% CI 0.63-1.40, P = 0.76; NRM, cause-specific HR 1.25, 95% CI 0.73-2.14, P = 0.41) (Figures 1a and b) . There was no significant impact of TMA on relapse rate (cause-specific HR 0.48, 95% CI 0.15-1.5, P = 0.21) (Figure 1c ).
Serum marker profiles of TMA and CKD at disease onset CKD and TMA were compared using routine laboratory parameters and endothelial serum markers at disease onset. Kidney function measured by glomerular filtration rate (modification of diet in renal disease (MDRD) formula) did not differ between the two cohorts (P = 0.719). Likewise, complement factor 3 (C3, P = 0.277), C4 (P = 0.391) and vascular endothelial growth factor levels (normalized to the thrombocyte counts) (P = 0.256) showed no differences between the two cohorts (Supplementary Figure 2) . In contrast, the endothelial serum markers sCD141 and ST2 were significantly higher in TMA compared with CKD (sCD141: 7.6 (5.0-12.7) vs 5.6 (2.3-11.5) ng/mL, P = 0.039; ST2: 9229 (838-20 000) vs 1281 (484-8360) pg/mL, P o 0.001) (Figure 1d ).
Furthermore, serum levels of ST2 and sCD141 correlated at disease onset of TMA (Kendall-Tau-b correlation coefficient 0.239; P o0.001).
Interactions of TMA and refractory GvHD Patients with aGvHD were grouped into sensitive (grades 1-4) and refractory GvHD. Both aGvHD and TMA are time-dependent variables. The co-incidence of TMA and aGvHD within the first year after transplantation was statistically significant (P o 0.001, Fisher's exact test, Table 2 ). The incidence of TMA in patients with refractory GvHD was estimated to be 45% and thus highly increased compared with patients with sensitive GvHD (4.5%) or without GvHD (1.1%; Table 2 ). Within this cohort, GvHD preceded TMA in 13 out of 18 cases with a median time of 29 days (12-112). TMA preceded GvHD in 5 out of 18 cases with a median time of 9 days (1-104). Survival at 2 years for patients without both TMA and refractory aGvHD, with TMA only, with refractory aGvHD only and with both TMA and refractory aGvHD was 72%, 39%, 28% and 10%, respectively (Figure 2a) . In contrast, CKD did not affect survival in patients without or with refractory GvHD (Figure 2b ).
Influence of statin-based endothelial protection (SEP) on TMA Statins and UDCA were introduced into the routine prophylactic regimen of all patients undergoing alloSCT after January 2010 and June 2010, respectively. Therefore, patients with statins and/or UDCA are summarized as our cohort with statin-based endothelial protection (SEP). These patients represent an independent, chronologically consecutive cohort of patients with higher age, lower percentage of related donors and lower proportion of lymphatic high-risk than intermediate-risk disease. 5 In order to estimate the potential influence of SEP on TMA incidence, we performed a multivariate multistate analysis with age, disease stage by EBMT score criteria, donor type, donor gender, MMF and strength of conditioning as baseline co-variables. The absorbing stage was relapse. SEP highly and independently reduced the risk of TMA (HR 0.23, 95% CI 0.11-0.49, P o 0.001). Apart from SEP, female donor sex, reduced intensity conditioning and MMF prophylaxis were the variables significantly affecting the TMA risk. Similarly, SEP associated with a trend to lower risk of acute refractory GvHD (HR 0.62, 95% CI 0.38-1.00, P = 0.052) ( Table 3) .
Endothelial markers before conditioning therapy and TMA The known endothelial vulnerability markers ANG2 and nitrates (both pretransplant serum levels) together with recipient's gene variants of THBD (SNPs rs1962, rs1042579 and rs1042580) 6 and the new marker ST2 were correlated with the incidence of TMA.
In patients transplanted before the introduction of SEP, high pretransplant levels of ANG2 did not associate with TMA (HR 1.22, 95% CI 0.44-3.37, P = 0.696) (Figure 3a) . However, the genetic high-risk group of THBD SNPs was at a significantly higher risk of TMA (HR 2.57, 95% CI 1.10-6.00 P = 0.029, compared with the low risk group), as were patients with high pretransplant nitrate levels (cutoff 26.5 μM, HR 2.29, 95% CI 0.94-5.61, P = 0.069). Moreover, high pretransplant ST2 serum levels were strongly associated with TMA (P = 0.040, bias correction see Methods) ( Figure 3a) . Of note, the predictive value of endothelial biomarkers completely disappeared under SEP (Supplementary Figure 3) . The strongest effects of SEP were observed in patients with a high-risk endothelial vulnerability serum marker profile (Supplementary Figure 4) .
As TMA independently impacts survival, we investigated whether our panel of endothelial vulnerability markers also associated with outcome in the absence of TMA. THBD-SNPs, pretransplant nitrate and ST2 serum levels did not predict OS after aGvHD in the absence of TMA, whereas high pretransplant ANG2 Abbreviations: AA = aplastic anemia; Aplasia conditioning = sequential intermediate intensity chemotherapy followed by RIC; MAC = myeloablative conditioning; MM = multiple myeloma; MMUD = mismatched unrelated donor; MPS = myeloproliferative syndrome; MUD = matched unrelated donor; NA = not available; NRM = non-relapse mortality; PD = progressive disease; PNH = paroxysmal nocturnal hemoglobinuria; RD = related donor; RIC = reduced intensity conditioning; SCT = stem cell transplantation; SEP = statin based endothelial protection. P-values were calculated using the Fisher's exact and Kruskal-Wallis tests.
a Twenty-seven patients received statin prophylaxis before January 2010 for pre-existing cardiac disorders.
b Kruskal-Wallis test.
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DISCUSSION
In this retrospective study, we find a strong association between TMA and refractory GvHD. Soluble thrombomodulin (sCD141) and ST2 highly associated with TMA at disease onset. Both serum markers allow differentiation of TMA from kidney diseases of other origin after alloSCT. Moreover, statin-based endothelial protection (SEP) associated with reduced incidence of TMA. This is in line with our previous observation of preventive statin effects on GvHD mortality in endothelial high-risk patients. 5 Furthermore, high pretransplant ST2 serum levels were specific for TMA: they associated with higher risk of TMA but did not predict death after aGvHD in the absence of TMA.
TMA is a fatal complication after alloSCT with a complex pathophysiology. Atypical hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura are closely related diseases; however, ADAMTS13 deficiency is not involved in TMA. 26 TMA affects kidneys and occasionally also lungs, heart and central nervous system. 27 In addition, isolated TMA of the gut was reported. 28, 29 A variety of risk factors were reported for TMA including aGvHD, use of total body irradiation, advanced age, female sex, advanced hematologic malignancy, use of unrelated donor transplant, non-myeloablative transplant, high-dose busulfan and HLA mismatch. 30 Endothelial distress has been recognized as the 'common final pathway' in TMA causing end-organ damage. 31 Diagnosis of TMA is challenging. Current diagnostic criteria include primarily changes in blood cell counts; 20 however, all of these markers are strongly influenced by the transplantation regime. More specific parameters to separate TMA from other post-alloSCT complications are lacking 32 and renal biopsy is rarely an option owing to thrombocytopenia. To date, TMA was designated as a 'diagnostic dilemma' and thus reported incidences are highly variable in different studies ranging from 1% to 64%. 7 However, our TMA cohort showed remarkably specific clinical features. We found that OS was strongly reduced in TMA patients independent of the occurrence of refractory GvHD. The coincidence of both complications (TMA and refractory GvHD) had the worst prognosis and was observed in approximately 45% of patients with refractory GvHD and 53% of patients with TMA. In contrast, survival was not affected in patients with isolated CKD. Given the strong disparity in survival between CKD and TMA, there No TMA  351  188  22  561  TMA  4  9  18  31  Total  355  197  40  592 Abbreviations: AlloSCT = allogeneic stem cell transplantation; TMA, transplant-associated microangiopathy. Fisher's exact test, Po 0.001 a Approximation for the correlation analysis of the two time to event variables within a competing risks situation. In order to minimize the influence of time on the analysis of co-incidence of the diseases, we only included patients into the GvHD/TMA cohorts if their GvHD and/or TMA occurred within the first year after alloSCT and all patients without any of the two diseases during the first year. Patients (179) who died in the first year without prior TMA and aGvHD were excluded from this comparison. Exclusion: no TMA, no GvHD: n = 99; aGvHD, no TMA: n = 74; TMA, no aGvHD: n = 6.
Transplant-associated thrombotic microangiopathy and acute GVHD M Zeisbrich et al Abbreviations: Aplasia = aplasia conditioning: sequential intermediate intensity chemotherapy followed by RIC; ATG = anti-thymocyte globulin; CI = confidence interval; HR = hazard ratios; MAC = myeloablative conditioning; MMF = mycofenolate mofetil; RIC = reduced intensity conditioning; SEP = statin-based endothelial protection; TMA = transplant-associated microangiopathy. All patients, n = 765; multivariate stage model, absorbing stage is relapse. is an urgent need to find biomarkers that allow us to distinguish these two renal complications at disease onset. Compared with patients with isolated CKD, we found a specific serological marker signature in TMA patients with high sCD141 and ST2 levels at disease onset. Therefore, sCD141 and ST2 are both potential biomarkers for TMA, as well as for predicting survival rates in patients with refractory GvHD. Whereas sCD141 is an acknowledged endothelial distress marker, ST2 is used as a prognostic biomarker in numerous clinical scenarios, suggesting that ST2 levels may simply reflect the severity of tissue damage, regardless of its initiating pathophysiology. 33 However, apart from the close correlation between sCD141 and ST2 in the present study, there are several lines of evidence, indicating that ST2 has an endothelial background: in experimental models, soluble ST2 was associated with the development of atherosclerotic plaques 34 and myocardial infarction. 35 In the Framingham Heart Study, a community cohort of 43300 participants with a mean age of 59 ± 10 years, soluble ST2 was an independent predictor of diabetes and blood pressure, 36 as well as of multiple cardiovascular outcomes including death, heart failure and major cardiovascular events. 37 Consistent with this observation, recent studies provide evidence that vascular endothelium is a main source of soluble ST2. 12, 38 Van der Lugt et al. 11 reported an association of soluble ST2 with resistance to GvHD therapy and death after alloSCT. ST2 was also confirmed as risk marker for aGvHD after cord blood transplantation. 39 Statins are widely used to lower serum cholesterol levels to help prevent atherosclerosis and coronary heart disease. However, their beneficial effects extend beyond their lipid lowering activity. The pleiotropic effects of statins include immunological effects (repression of MHC-II-mediated T-cell activation, 40 lowering C-reactive protein levels, 41 inhibition of interferon-α secretion from dendritic cells 42 and reducing T-cell cytotoxity 43 ) as well as improvement of endothelial function. 44 Indeed, pravastatin was reported to preserve microvascular endothelial function in the presence of hyperglycemia in experimental diabetic renal disease and inhibit the early stage of diabetic microangiopathy. 45 However, statins were not yet explored in TMA and atypical hemolytic-uremic syndrome -like diseases. Our data represent first evidence that statin therapy may reduce the risk of TMA after alloSCT.
UDCA is a hydrophilic bile acid promoting hydrocholeresis that is necessary to maintain a protective bicarbonate shield of cholangiocytes against bile acids. 46 In the setting of alloSCT, UDCA was shown to reduce NRM in a randomized clinical trial due to lower rates of high-grade GvHD. 47 In our own cohort, we did not find additional effects of UDCA in statin patients with regards to NRM or TMA incidence (Supplementary Figure 1) . However, potential additional influences of UDCA on endothelial protection cannot be excluded in this retrospective study.
Endothelial vulnerability was previously defined for patients not receiving SEP: the endothelial-associated serum markers were measured before conditioning therapy (ANG2 and nitrates [3] [4] [5] ) and also included genetic variants in the thrombomodulin gene (THBD) of the recipient. 6 The present study found that only half of refractory GvHD patients developed TMA. Therefore, we investigated whether these endothelial markers (ANG2, nitrates and SNPs in THBD) together with ST2, as a novel marker, associate with TMA. Interestingly, nitrates, ST2 and THBD-SNPs associated with TMA and its high mortality, but not with mortality in the absence of TMA. In contrast, ANG associated with mortality only in patients without TMA. These data suggest the existence of two different pathomechanisms underlying refractoriness of GvHD. Although ST2 along with nitrates and THBD-SNPs specifically predict mortality in the setting of TMA, ANG2 associates only with mortality from refractory GvHD and not with mortality from TMA.
Although this study was done retrospectively and patient cohorts with and without SEP were collected sequentially rather than concurrently, our results demonstrate a strong but not exclusive co-incidence of TMA and refractory GvHD. TMA was characterized at disease onset by endothelial markers such as sCD141 and ST2. Moreover, statin-based endothelial protection appears to reduce the incidence of TMA. Taken together, these results demonstrate that TMA is one clinical link between endothelial vulnerability and GvHD refractoriness. Practical consequences of these findings could be the prophylactic use of statin-based endothelial protection at least in patients with an unfavorable endothelial biomarker profile and avoiding settings with high risk of GvHD, such as mismatch transplants, in patients with documented pretransplant endothelial vulnerability. However, the absence of TMA in a proportion of refractory GvHD patients indicates that there might be additional pathways important to GvHD refractoriness. The pathophysiology of refractory aGvHD without TMA and the mechanism of TMA episodes occurring despite SEP require further study.
